BPA Call 36E79726A0012-36C24526N0825
Award Date 8/20/26
Potential Completion Date 8/25/26
Potential Value $38K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Not listed Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Brooks, KY 40109, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Veterans Integrated Service Network 5 issued a BPA call to Takeda Pharmaceuticals America, Inc. on July 28, 2026, with a ceiling value of $34,605.34 under a Blanket Purchase Agreement for pharmaceutical supply. Ultimate completion is July 29, 2026. Place of performance is Carrollton, Texas. The call procures ICLUSIG (ponatinib) tablets, a specialty oncology pharmaceutical for chronic myeloid leukemia and acute lymphoblastic leukemia, under firm fixed price terms. This represents a routine...
- On January 15, 2026, the Department of Veterans Affairs, Veterans Integrated Service Network 5, awarded a delivery order valued at $38,097.52 to Takeda Pharmaceuticals America Inc. for TAKHZYRO 150 MG, a specialized pharmaceutical product used to treat rare genetic disorders. This firm fixed-price delivery order, with an ultimate completion date of January 20, 2026, represents a child contract under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB) and does not utilize a set-aside...
- On November 7, 2025, the Department of Veterans Affairs, Veterans Integrated Service Network 5, awarded a firm fixed-price delivery order valued at $36,984.28 to Takeda Pharmaceuticals America Inc. for the supply of TAKHZYRO 150 MG, a specialized pharmaceutical treatment for hereditary angioedema. This delivery order represents a child contract under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB) and carries an ultimate completion date of November 13, 2025. The award was made without a...
- On December 16, 2025, the Department of Veterans Affairs Veterans Integrated Service Network 5 awarded a firm fixed-price delivery order valued at $36,984.28 to Takeda Pharmaceuticals America Inc. for the supply of TAKHZYRO 150 mg, a specialized pharmaceutical treatment for hereditary angioedema. This delivery order represents a child contract under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB) and carries an ultimate completion date of December 18, 2025. The contract was awarded...
- Takeda Pharmaceuticals America, Inc. was awarded a delivery order against its Pharmaceuticals and Drugs Federal Supply Schedule contract for $43,471.17 to provide ICLUSIG (ponatinib) to the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20. The order has a completion date of April 29, 2024 and was awarded on February 29, 2024 under a firm fixed price arrangement. Takeda Pharmaceuticals America currently holds an active blanket purchase agreement...
- The U.S. Department of Veterans Affairs (VA) awarded a Blanket Purchase Agreement (BPA) call order to Takeda Pharmaceuticals America, Inc. to supply the oncology medication ICLUSIG (ponatinib) 15mg to VA medical facilities nationwide. This $39,130.29 firm-fixed-price contract was placed against Takeda's existing General Services Administration (GSA) Schedule 61-IB for Pharmaceuticals and Drugs and has an ultimate completion date of August 2, 2024. The parent company of the prime contractor,...
- This federal contract award is for the pharmaceutical product TAKHZYRO 150 MG, awarded to Takeda Pharmaceuticals America Inc., a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited. The contract has a ceiling value of $36,984.28 and was awarded on September 18, 2025, with an ultimate completion date of September 23, 2025. The contract was awarded under the General Services Administration (GSA) Pharmaceuticals and Drugs Schedule (FSS-61-IB) and does not have a...
- This federal contract award was issued by the Veterans Integrated Service Network 22 (VISN 22), which is part of the U.S. Department of Veterans Affairs (VA), to Takeda Pharmaceuticals America, Inc., a subsidiary of the Japan-based Takeda Pharmaceutical Company Limited. The $57,422.55 firm-fixed-price contract is for the delivery of emergency medications, primarily specialty oncology drugs such as ICLUSIG (ponatinib) and NINLARO (ixazomib), to various VA medical facilities across the country....
- This is a firm-fixed-price delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract is for the supply of ICLUSIG 15 MG, a specialty oncology medication, to VA medical facilities. The contract has a ceiling value of $14,197.39 and a completion date of October 8, 2025. Takeda Pharmaceuticals America, Inc. holds a $123.5 million Blanket Purchase Agreement (BPA) with the VA...
- This federal contract award is for the pharmaceutical product TAKHZYRO 150 MG, which was awarded to Takeda Pharmaceuticals America Inc., a subsidiary of the global biopharmaceutical company Takeda Pharmaceutical Company Limited. The contract, valued at $36,984.28, is a delivery order with a firm fixed-price pricing type, and the ultimate completion date is August 27, 2025. The contract was awarded by the Veterans Integrated Service Network 5, a civilian defense agency, and is part of the General...